Physician profile
Dora Cantu
NPI 1194725366
$1,493.73
in general payments reported to CMS, 2019-2025
13 companies · $34.79 in 2025
The $34.79 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.28 · 2020: $50.06 · 2021: $218 · 2022: $379 · 2023: $313 · 2024: $401 · 2025: $34.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $749.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $848.95 | 2019-2024 | |
| Tarsus Pharmaceuticals, INC. | $139.87 | 2024 | Xdemvy |
| Alcon Vision LLC | $92.90 | 2019-2024 | Clareon |
| Sun Pharmaceutical Industries INC. | $63.41 | 2024 | |
| Carl Zeiss Meditec USA, INC. | $56.82 | 2022 | |
| Harrow Eye, LLC | $55.99 | 2024 | Vevye |
| Oyster Point Pharma, INC. | $54.38 | 2022-2023 | Tyrvaya |
| Aerie Pharmaceuticals, INC. | $50.06 | 2020 | |
| Bausch & Lomb Americas INC. | $43.98 | 2022-2024 | Toric |
| Sight Sciences, INC. | $34.79 | 2025 | Omni Surgical System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $23.23 | 2019 | |
| Kala Pharmaceuticals, INC. | $17.78 | 2022 | |
| Allergan, INC. | $11.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dora Cantu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.